The Cancer Prevention and Research Institute of Texas (CPRIT), an institute that provides funding through its academic research, prevention and product development research programs, recently revealed the recipients of 5 grants awarded through its academic research program. Worth a total of $17,700,000, these grants will fund the recruitment of 5 skilled cancer scientists to 4 academic institutions in the state of Texas. This series of research grants adds to the institution’s almost 100 awarded grants that are worth a total of approximately $292.1 million.
“To advance the fight against cancer, you need to have the very best scientists, and these new awards mean that CPRIT has attracted another five top researchers to Texas,” said the agency’s chief executive officer Wayne Roberts in a press release.
The grants awarded assisted academic institutions in the state to attract two accomplished emerging scientists whose work is centered on breast and ovarian cancer. Another pair of scientists will be absorbed into their first faculty appointments, and the fifth will be bringing his expertise in computational biology from the Vanderbilt University to The University of Texas at Austin.
The Scientific Review Council of the CPRIT stringently evaluated these grants and recommended the following scientists:
- Thomas Yankeelov, PhD., from the Vanderbilt University to The University of Texas at Austin ($6,000,000 grant)
- Chonghui Cheng, M.D., PhD., from Northwestern University Feinberg School of Medicine to Baylor College of Medicine ($4,000,000 grant)
- Wa Xian, PhD., from the University of Connecticut to The University of Texas Health Science Center at Houston ($3,700,000 grant)
First-Time, Tenure-Track Faculty Members:
- Ronald Parchem, PhD., from the University of California at San Francisco to Baylor College of Medicine ($2,000,000 grant)
- Peter Douglas, PhD., from the University of California, Berkeley to The University of Texas Southwestern Medical Center ($2,000,000)
A study recently published in the journal Cancer revealed that beta-blocker agents can increase the survival rate in ovarian cancer patients. The study was led by researchers at The University of Texas MD Anderson Cancer Center and Washington University School of Medicine, and is entitled “Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.”